Systemic immune inflammation index and gastric cancer prognosis: A systematic review and meta‑analysis

Yang,Xiaomao; Wu,Chen

doi:10.3892/etm.2024.12410

Systemic immune inflammation index and gastric cancer prognosis: A systematic review and meta‑analysis

Authors:
- Xiaomao Yang
- Chen Wu
View Affiliations

Affiliations: Department of Gastrointestinal Hernia, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang 313000, P.R. China
Published online on: February 1, 2024 https://doi.org/10.3892/etm.2024.12410
Article Number: 122
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to pool the available data on the associations between the systemic immune inflammation index (SII) and overall survival (OS) or recurrence‑free survival (RFS) in patients with gastric cancer (GC). A systematic search was conducted in the PubMed, EMBASE and Scopus databases for observational studies, and a random effects model was used to conduct the statistical analysis. Pooled effect sizes were reported as hazard ratios (HRs) with corresponding 95% confidence intervals (CI). Data from 30 studies (24 conducted in China) with follow‑ups ranging between 15.5 and 65.6 months were analyzed. Patients with GC and high SII levels had poor OS (HR, 1.53; 95% CI, 1.34‑1.75) and recurrence free survival (HR, 1.41; 95% CI, 1.17‑1.70). These increased risks were present irrespective of the treatment strategy (surgical or non‑surgical management), the sample size (<500 and ≥500) and the cut‑off used to define high and low SII (<600 and ≥600 x10⁹ cells/l). The results of this meta‑analysis suggest that high pretreatment SII levels were associated with poor OS and RFS in patients with GC.

View Figures

View References

1	World Health Organization: Cancer Fact Sheets: Stomach Cancer. WHO, Geneva, 2020.
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
3	Song Y, Liu X, Cheng W, Li H and Zhang D: The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019. Sci Rep. 12(11542)2022.PubMed/NCBI View Article : Google Scholar
4	GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 5:42–54. 2020.PubMed/NCBI View Article : Google Scholar
5	Maconi G, Manes G and Porro GB: Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 14:1149–1155. 2008.PubMed/NCBI View Article : Google Scholar
6	Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R and Polkowski WP: Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res. 10:239–248. 2018.PubMed/NCBI View Article : Google Scholar
7	Boniface MM, Wani SB, Schefter TE, Koo PJ, Meguid C, Leong S, Kaplan JB, Wingrove LJ and McCarter MD: Multidisciplinary management for esophageal and gastric cancer. Cancer Manag Res. 8:39–44. 2016.PubMed/NCBI View Article : Google Scholar
8	Guan WL, He Y and Xu RH: Gastric cancer treatment: Recent progress and future perspectives. J Hematol Oncol. 16(57)2023.PubMed/NCBI View Article : Google Scholar
9	Song Z, Wu Y, Yang J, Yang D and Fang X: Progress in the treatment of advanced gastric cancer. Tumour Biol. 39(1010428317714626)2017.PubMed/NCBI View Article : Google Scholar
10	Shah MA and Ajani JA: Gastric cancer-an enigmatic and heterogeneous disease. JAMA. 303:1753–1754. 2010.PubMed/NCBI View Article : Google Scholar
11	Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, et al: Gastric cancer, version 2.2013: Featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 11:531–546. 2013.PubMed/NCBI View Article : Google Scholar
12	Liu J, Lin PC and Zhou BP: Inflammation fuels tumor progress and metastasis. Curr Pharm Des. 21:3032–3040. 2015.PubMed/NCBI View Article : Google Scholar
13	Greten FR and Grivennikov SI: Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity. 51:27–41. 2019.PubMed/NCBI View Article : Google Scholar
14	Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C and Cheng Y: Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 33(e22964)2019.PubMed/NCBI View Article : Google Scholar
15	Wang S, Yang X, Yu Z, Du P, Cao Y, Ji Y, Ma J and Yang Y: The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in predicting testicular germ cell tumors: A retrospective clinical study. Front Oncol. 12(893877)2022.PubMed/NCBI View Article : Google Scholar
16	Xia LJ, Li W, Zhai JC, Yan CW, Chen JB and Yang H: Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer. BMC Cancer. 20(208)2020.PubMed/NCBI View Article : Google Scholar
17	Zhu S, Cheng Z, Hu Y, Chen Z, Zhang J, Ke C, Yang Q, Lin F, Chen Y and Wang J: Prognostic value of the systemic immune-inflammation index and prognostic nutritional index in patients with medulloblastoma undergoing surgical resection. Front Nutr. 8(754958)2021.PubMed/NCBI View Article : Google Scholar
18	Huang Y, Gao Y, Wu Y and Lin H: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: A meta-analysis. Cancer Cell Int. 20(499)2020.PubMed/NCBI View Article : Google Scholar
19	Yang R, Chang Q, Meng X, Gao N and Wang W: Prognostic value of systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 9:3295–3302. 2018.PubMed/NCBI View Article : Google Scholar
20	Li X, Zhang S, Lu J, Li C and Li N: The prognostic value of systemic immune-inflammation index in surgical esophageal cancer patients: An updated meta-analysis. Front Surg. 9(922595)2022.PubMed/NCBI View Article : Google Scholar
21	Hong X, Cui B, Wang M, Yang Z, Wang L and Xu Q: Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 236:297–304. 2015.PubMed/NCBI View Article : Google Scholar
22	Qiu Y, Zhang Z and Chen Y: Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: A meta-analysis. Front Oncol. 11(537140)2021.PubMed/NCBI View Article : Google Scholar
23	Fu S, Yan J, Tan Y and Liu D: Prognostic value of systemic immune-inflammatory index in survival outcome in gastric cancer: A meta-analysis. J Gastrointest Oncol. 12:344–354. 2021.PubMed/NCBI View Article : Google Scholar
24	Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Losos M and Tugwell P: The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed on April 29, 2023.
25	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
26	Egger M, Smith GD, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997.PubMed/NCBI View Article : Google Scholar
27	Gu L, Wang M, Cui X, Mo J, Yuan L, Mao F, Zhang K, Ng DM, Chen P and Wang D: Clinical significance of peripheral blood-derived inflammation markers in advanced gastric cancer after radical resection. BMC Surg. 20(219)2020.PubMed/NCBI View Article : Google Scholar
28	Demircan NC, Atcı MM, Demir M, Işık S and Akagündüz B: Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy. Asia Pac J Clin Oncol. 19:104–112. 2023.PubMed/NCBI View Article : Google Scholar
29	Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H and Otsuji E: Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol. 19(173)2021.PubMed/NCBI View Article : Google Scholar
30	Wei C, Li C, Chen X, Chen G, Nie R, Zhao C, Zhou Z and Chen Y: Development and verification of a nomogram for predicting the prognosis of resectable gastric cancer with outlet obstruction. BMC Cancer. 22(1154)2022.PubMed/NCBI View Article : Google Scholar
31	Zhaojun X, Xiaobin C, Juan A, Jiaqi Y, Shuyun J, Tao L, Baojia C, Cheng W and Xiaoming M: Correlation analysis between preoperative systemic immune inflammation index and prognosis of patients after radical gastric cancer surgery: Based on propensity score matching method. World J Surg Oncol. 20(1)2022.PubMed/NCBI View Article : Google Scholar
32	Wang SB, Chen JY, Xu C, Cao WG, Cai R, Cao L and Cai G: Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Front Oncol. 12(1040495)2022.PubMed/NCBI View Article : Google Scholar
33	Qu Z, Wang Q, Wang H, Jiao Y, Li M, Wei W, Lei Y, Zhao Z, Zhang T, Zhang Y and Gu K: The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy. Front Oncol. 12(783197)2022.PubMed/NCBI View Article : Google Scholar
34	Wan M, Ding Y, Mao C, Ma X, Li N, Xiao C, Qian J, Jiang H, Zheng Y, Wu L, et al: Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment. Front Oncol. 12(1029960)2022.PubMed/NCBI View Article : Google Scholar
35	Yekedüz E, Dogan İ, Kaya D, MÖzgür İ, Utkan G, Vatansever S, Demirci S, Akbulut H and Ürün Y: Systemic immune-inflammation index as a prognostic marker of late recurrence in operable gastric cancer: A dual-center study. J Gastrointest Cancer. 53:870–879. 2022.PubMed/NCBI View Article : Google Scholar
36	Liu YY, Ruan GT, Ge YZ, Li QQ, Zhang Q, Zhang X, Tang M, Song MM, Zhang XW, Li XR, et al: Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer. J Cancer Res Clin Oncol. 149:1249–1259. 2023.PubMed/NCBI View Article : Google Scholar
37	Uzunoglu H and Kaya S: Does systemic immune inflammation index have predictive value in gastric cancer prognosis? North Clin Istanb. 10:24–32. 2023.PubMed/NCBI View Article : Google Scholar
38	Wang H, Yin X, Ma K, Wang Y, Fang T, Zhang Y and Xue Y: Nomogram based on preoperative fibrinogen and systemic immune-inflammation index predicting recurrence and prognosis of patients with borrmann type III advanced gastric cancer. J Inflamm Res. 16:1059–1075. 2023.PubMed/NCBI View Article : Google Scholar
39	He K, Si L, Pan X, Sun L, Wang Y, Lu J and Wang X: Preoperative systemic immune-inflammation index (SII) as a superior predictor of long-term survival outcome in patients with stage I-II gastric cancer after radical surgery. Front Oncol. 12(829689)2022.PubMed/NCBI View Article : Google Scholar
40	Chen Y, Zhang C, Peng Z, Qi C, Gong J, Zhang X, Li J and Shen L: Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor. Front Oncol. 11(589022)2021.PubMed/NCBI View Article : Google Scholar
41	Shi H, Wang H, Pan J, Liu Z and Li Z: Comparing prognostic value of preoperative platelet indexes in patients with resectable gastric cancer. Sci Rep. 12(6480)2022.PubMed/NCBI View Article : Google Scholar
42	Wang PX, Wang HJ, Liu JH, Qiu GL, Lu J, Fan L, Liao XH and Che XM: A nomogram combining plasma fibrinogen and systemic immune-inflammation index predicts survival in patients with resectable gastric cancer. Sci Rep. 11(10301)2021.PubMed/NCBI View Article : Google Scholar
43	Huang L, Liu S, Lei Y, Wang K, Xu M, Chen Y, Liu B, Chen Y, Fu Q, Zhang P, et al: Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget. 7:44185–44193. 2016.PubMed/NCBI View Article : Google Scholar
44	Chen L, Yan Y, Zhu L, Cong X, Li S, Song S, Song H and Xue Y: Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 9:849–867. 2017.PubMed/NCBI View Article : Google Scholar
45	Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren H, Li T, Wu H, He Y, Cai S and Chen J: Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer. 36(75)2017.PubMed/NCBI View Article : Google Scholar
46	Guo J, Chen S, Chen Y, Li S and Xu D: Combination of CRP and NLR: A better predictor of postoperative survival in patients with gastric cancer. Cancer Manag Res. 10:315–321. 2018.PubMed/NCBI View Article : Google Scholar
47	Shi H, Jiang Y, Cao H, Zhu H, Chen B and Ji W: Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients. Dis Markers. 2018(1787424)2018.PubMed/NCBI View Article : Google Scholar
48	Wang Q and Zhu D: The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol. 10:965–978. 2019.PubMed/NCBI View Article : Google Scholar
49	Yılmaz A, Mirili C, Tekin SB and Bilici M: The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: A retrospective study. Ir J Med Sci. 189:91–102. 2020.PubMed/NCBI View Article : Google Scholar
50	Hirahara N, Tajima Y, Matsubara T, Fujii Y, Kaji S, Kawabata Y, Hyakudomi R, Yamamoto T, Uchida Y and Taniura T: Systemic immune-inflammation index predicts overall survival in patients with gastric cancer: A propensity score-matched analysis. J Gastrointest Surg. 25:1124–1133. 2021.PubMed/NCBI View Article : Google Scholar
51	Lin JX, Wang ZK, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, Lin M, Tu RH, Huang ZN, et al: Dynamic changes in pre- and postoperative levels of inflammatory markers and their effects on the prognosis of patients with gastric cancer. J Gastrointest Surg. 25:387–396. 2021.PubMed/NCBI View Article : Google Scholar
52	Zhou W, Wu J, Wang Q, Zhang H, Jiang J and Wu C: Evaluate the correlation between preoperative systemic immune-inflammation index and prognosis of patients after curative resection for cardia gastric cancer. Chin Med Biotechnol. 11:510–514. 2016.(In Chinese).
53	Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y and Xu D: Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 8:339–345. 2015.PubMed/NCBI View Article : Google Scholar
54	Fang T, Yin X, Wang Y, Zhang L, Zhang X, Zhao X, Wang Y and Xue Y: Proposed models for prediction of mortality in stage-I and stage-II gastric cancer and 5 years after radical gastrectomy. J Oncol. 2022(4510000)2022.PubMed/NCBI View Article : Google Scholar
55	Yin X, Fang T, Wang Y, Li C, Wang Y, Zhang D and Xue Y: Efficacy of postoperative FOLFOX versus XELOX chemotherapy for gastric cancer and prognostic value of platelet-lymphocyte ratio in patients receiving XELOX. Front Oncol. 10(584772)2020.PubMed/NCBI View Article : Google Scholar
56	Zhu Z, Cong X, Li R, Yin X, Li C and Xue Y: Preoperative systemic immune-inflammation index (SII) for predicting the survival of patients with stage I-III gastric cancer with a signet-ring cell (SRC) component. BioMed Res Int. 2020(e5038217)2020.PubMed/NCBI View Article : Google Scholar
57	Zhong JH, Huang DH and Chen ZY: Prognostic role of systemic immune-inflammation index in solid tumors: A systematic review and meta-analysis. Oncotarget. 8:75381–75388. 2017.PubMed/NCBI View Article : Google Scholar
58	Wang Y, Li Y, Chen P, Xu W, Wu Y and Che G: Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: A meta-analysis. Ann Transl Med. 7(433)2019.PubMed/NCBI View Article : Google Scholar
59	Wang B, Huang Y and Lin T: Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 99(e18571)2020.PubMed/NCBI View Article : Google Scholar
60	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.PubMed/NCBI View Article : Google Scholar
61	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
62	Santoiemma PP and Powell DJ Jr: Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 16:807–820. 2015.PubMed/NCBI View Article : Google Scholar
63	Whiteside TL: Tumor-infiltrating lymphocytes and their role in solid tumor progression. Exp Suppl. 113:89–106. 2022.PubMed/NCBI View Article : Google Scholar
64	Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, Chen J, Liu D and Li C: Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: A systematic review and meta-analysis. Cancer Cell Int. 20(15)2020.PubMed/NCBI View Article : Google Scholar
65	Ménétrier-Caux C, Ray-Coquard I, Blay JY and Caux C: Lymphopenia in cancer patients and its effects on response to immunotherapy: An opportunity for combination with Cytokines? J Immunother Cancer. 7(85)2019.PubMed/NCBI View Article : Google Scholar
66	Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98:1652–1658. 2007.PubMed/NCBI View Article : Google Scholar
67	Masucci MT, Minopoli M and Carriero MV: Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 9(1146)2019.PubMed/NCBI View Article : Google Scholar
68	Xiong S, Dong L and Cheng L: Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 14(173)2021.PubMed/NCBI View Article : Google Scholar
69	Uribe-Querol E and Rosales C: Neutrophils in cancer: Two sides of the same coin. J Immunol Res. 2015(983698)2015.PubMed/NCBI View Article : Google Scholar
70	Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C and Panicot-Dubois L: Platelets, thrombo-inflammation, and cancer: Collaborating with the enemy. Front Immunol. 10(1805)2019.PubMed/NCBI View Article : Google Scholar
71	Gay LJ and Felding-Habermann B: Contribution of platelets to tumour metastasis. Nat Rev Cancer. 11:123–134. 2011.PubMed/NCBI View Article : Google Scholar